Gene Therapy Breakthrough: FDA Greenlights Deafness Treatment

The U.S. Food and Drug Administration (FDA) on Thursday approved Regeneron Pharmaceuticals' gene therapy for a rare inherited form of deafness, in what officials described as the first treatment cleared for genetic hearing loss. The authorization was issued under the FDA’s new priority voucher program, according to the announcement.

The therapy is called Otarmeni and is designed for otoferlin-related hearing loss. This condition is linked to variants in the OTOF gene, which can prevent normal hearing by disrupting a key step in how sound information is passed from the ear to the brain.

Regeneron said the treatment works by supplying a functional copy of the OTOF gene. The goal is to replace the non-functional otoferlin protein that results from the genetic variants, restoring the protein’s role in the inner ear’s hair cells, which are essential for transmitting sound signals.

Otarmeni uses a modified, non-pathogenic virus as the delivery vehicle for the gene. The company said the therapy is administered through an infusion directly into the cochlea, described as a bony cavity within the inner ear.

The FDA decision also highlights the agency’s use of its new priority voucher program in the context of rare diseases. The approval is tied to that pathway, which can influence how quickly certain applications are reviewed, based on the program’s design.

Regeneron said Otarmeni will be provided free of charge to eligible patients in the United States. The company did not provide additional details in the announcement on how eligibility will be determined or how patients and clinicians should access the program.

For healthcare systems and investors, the clearance places gene therapy for hearing loss into a new regulatory category: an FDA-approved option for a defined genetic target. At the same time, the immediate reach is limited by the rarity of the mutation, which is estimated to affect 20–50 newborns annually in the United States.

Key uncertainties remain based on the information released, including how quickly treatment centers can operationalize cochlear infusion procedures for eligible patients and how the free-of-charge commitment will function in practice. Further implementation details are expected to shape uptake and access within the U.S. market.